INCY Novinky na Forexe
Incyte Q4 Adj EPS Misses Estimates, But Revenues Top
Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.
RTTNews
|
Pred 381 dňami
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets
Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).
RTTNews
|
Pred 707 dňami
Incyte Q1 Results Top Estimates
Incyte Corp. (INCY) on Tuesday reported net income of $161.43 million or $0.72 per share for the first quarter, up from $149.46 million or $0.67 per share in the prior-year quarter.
RTTNews
|
Pred 941 dňami
